Viral Pathogens
Lead Research Organisation:
London Sch of Hygiene & Tropic. Medicine
Department Name: UNLISTED
Abstract
Infections caused by viruses remain a major public health challenge especially HIV with no vaccine or a cure and emerging and re-emerging infections like SARS-CoV-2 and Ebola. Our close affiliation to Uganda Virus Research Institute which is one of the few institutes in Africa dedicated to virus research, and the strong links to the Uganda Ministry of Health (MOH) enable the Unit to have impact in addressing these infections.
The Viral Pathogen Theme has three focus areas: viral pathogen epidemiology and interventions (VPEI); viral pathogen discovery, diversity and impact on epidemic and disease outcome (VPDD); and oncogenic virus immunovirology (OVI). Our aims and key objectives for each of the above focus areas will include:
1) VPEI: We will undertake research on the epidemiology & prevention of HIV, oncogenic and emerging/re-emerging viral infections, associated co-infections, and studies to improve long-term health conditions.
2) VPDD: We will contribute to the discovery of emerging viruses of public health importance and understand how viral diversity affects epidemics and disease outcome
3) OVI: We will also study oncogenic viruses and their host interactions in order to contribute to cancer prevention and control
In the areas of VPEI and OVI, our work will include rigorous social science research to understand the social determinants of disease, to design appropriate interventions, and to study factors that influence uptake of interventions.
The Viral Pathogen Theme has three focus areas: viral pathogen epidemiology and interventions (VPEI); viral pathogen discovery, diversity and impact on epidemic and disease outcome (VPDD); and oncogenic virus immunovirology (OVI). Our aims and key objectives for each of the above focus areas will include:
1) VPEI: We will undertake research on the epidemiology & prevention of HIV, oncogenic and emerging/re-emerging viral infections, associated co-infections, and studies to improve long-term health conditions.
2) VPDD: We will contribute to the discovery of emerging viruses of public health importance and understand how viral diversity affects epidemics and disease outcome
3) OVI: We will also study oncogenic viruses and their host interactions in order to contribute to cancer prevention and control
In the areas of VPEI and OVI, our work will include rigorous social science research to understand the social determinants of disease, to design appropriate interventions, and to study factors that influence uptake of interventions.
Technical Summary
Infections caused by viruses remain a major public health challenge especially HIV with no vaccine nor a cure and emerging and re-emerging infections like SARS-CoV-2 and Ebola. Our close affiliation to Uganda Virus Research Institute which is one of the few institutes in Africa dedicated to virus research, strong links to the Uganda Ministry of Health enable the Unit to have impact in addressing these viral infections.
The Viral Pathogen Theme has three focus areas: viral pathogen epidemiology and interventions (VPEI); viral pathogen discovery, diversity and impact on epidemic and disease outcome (VPDD); and oncogenic virus immunovirology (OVI). Our aims and key objectives for each of the above focus areas will include:
1) VPEI: To undertake research on the epidemiology & prevention of HIV, oncogenic and emerging/re-emerging viral infections, associated co-infections, and to improve long-term health conditions. The key objectives are to quantify the magnitude and trends of HIV infection and mortality in general and key populations, to inform interventions for HIV prevention and treatment; to quantify the magnitude and trends of SARS-CoV-2 in relation to infecting variants, HIV co-infection, vaccination, and long-term health; to develop new interventions and expand coverage of existing tools for HIV prevention and treatment and to improve the long term health of persons living with HIV; to identify the environmental correlates of viral control of Kaposi’s sarcoma associated herpesvirus (KSHV) in the oral cavity and systemically, to allow development of targeted intervention strategies in the future, to decrease transmission and pathogenicity, thereby reducing the substantial burden of KS in the region.
2) VPDD: To contribute to the discovery of emerging viruses of public health importance and understand how viral diversity affects epidemics and disease outcome. Key objectives are to identify new and re-emerging viruses of potential public health importance; to study the emerging HIV Drug Resistance patterns and their predictors especially in the era of integrase inhibitors, protease inhibitors, and PrEP; to investigate how HIV and SARS-CoV2 diversity affect immune protection.
3) OVI: To study oncogenic viruses and their host interactions in order to contribute to cancer prevention and control. We will study the virological and immunological factors that contribute to sustain high levels of KSHV transmission and disease on the continent.
In the areas of VPEI and OVI, our work will include rigorous social science research to understand the social determinants of disease, to design appropriate interventions, and to study factors that influence uptake of interventions.
The Viral Pathogen Theme has three focus areas: viral pathogen epidemiology and interventions (VPEI); viral pathogen discovery, diversity and impact on epidemic and disease outcome (VPDD); and oncogenic virus immunovirology (OVI). Our aims and key objectives for each of the above focus areas will include:
1) VPEI: To undertake research on the epidemiology & prevention of HIV, oncogenic and emerging/re-emerging viral infections, associated co-infections, and to improve long-term health conditions. The key objectives are to quantify the magnitude and trends of HIV infection and mortality in general and key populations, to inform interventions for HIV prevention and treatment; to quantify the magnitude and trends of SARS-CoV-2 in relation to infecting variants, HIV co-infection, vaccination, and long-term health; to develop new interventions and expand coverage of existing tools for HIV prevention and treatment and to improve the long term health of persons living with HIV; to identify the environmental correlates of viral control of Kaposi’s sarcoma associated herpesvirus (KSHV) in the oral cavity and systemically, to allow development of targeted intervention strategies in the future, to decrease transmission and pathogenicity, thereby reducing the substantial burden of KS in the region.
2) VPDD: To contribute to the discovery of emerging viruses of public health importance and understand how viral diversity affects epidemics and disease outcome. Key objectives are to identify new and re-emerging viruses of potential public health importance; to study the emerging HIV Drug Resistance patterns and their predictors especially in the era of integrase inhibitors, protease inhibitors, and PrEP; to investigate how HIV and SARS-CoV2 diversity affect immune protection.
3) OVI: To study oncogenic viruses and their host interactions in order to contribute to cancer prevention and control. We will study the virological and immunological factors that contribute to sustain high levels of KSHV transmission and disease on the continent.
In the areas of VPEI and OVI, our work will include rigorous social science research to understand the social determinants of disease, to design appropriate interventions, and to study factors that influence uptake of interventions.
Organisations
- London Sch of Hygiene & Tropic. Medicine (Lead Research Organisation)
- International AIDS Vaccine Initiative (IAVI) (Collaboration)
- Ministry of Health, Uganda (Collaboration)
- Africa Centres For Disease Control And Prevention (Collaboration)
- Wits Health Consortium (Collaboration)
- University of Colorado Denver (Collaboration)
- Johns Hopkins University (Collaboration)
- Abbott (Collaboration)
- University of Glasgow (Collaboration)
- European Union (Collaboration)
- Translational Health Science and Technology Institute (Collaboration)
- Public Assistance - Hospitals of Paris (Collaboration)
- Desmond Tutu HIV Foundation (Collaboration)
- Uganda Virus Research Institute (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- McMaster University (Collaboration)
- Francis Crick Institute (Collaboration)
- Centers for Disease Control and Prevention (CDC) (Collaboration)
- Sabin Vaccine Institute (Collaboration)
- Kenya AIDS Vaccine Initiative (KAVI) (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University of KwaZulu-Natal (Collaboration)
- Bill and Melinda Gates Foundation (Collaboration)
- La Jolla Institute for Immunology (Collaboration)
- Presidency of the Republic of Cameroon (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- Coalition for Epidemic Preparedness Innovations (Collaboration)
- UNIVERSITY COLLEGE LONDON (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- Institute of Bio-Resources and Sustainable Development (Collaboration)
- Government of Uganda (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
People |
ORCID iD |
| Pontiano Kaleebu (Principal Investigator) |
Publications
Abaasa A
(2023)
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial.
in Immunotherapy advances
Abaasa AM
(2025)
Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
in Vaccine
Abdullahi A
(2023)
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
in The Journal of antimicrobial chemotherapy
Aceng FL
(2024)
Correction: Rift valley fever outbreak in Sembabule District, Uganda, December 2020.
in One health outlook
Aceng FL
(2023)
Rift valley fever outbreak in Sembabule District, Uganda, December 2020.
in One health outlook
Alagaratnam J
(2024)
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial
in Journal of Virus Eradication
Anywaine Z
(2024)
Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.
in Virology journal
Ario AR
(2023)
Uganda's experience in establishing an electronic compendium for public health emergencies.
in PLOS global public health
| Description | 33. Member organising committee International Workshop on HIV Drug Resistance and Treatment Strategies |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | There has been changes in treatment guidelines and how resistance is beginning to develop during the time since Dolutegravir was introduced |
| Description | Chair TSC Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | This study has led to recommendations that long acting injectable antiretrovirals can used in individuals who have suppressed and there is preference for these drugs |
| Description | Chair of the UVRI-IAVI HIV vaccine Program Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | We have been able to advise on the research priorities including vaccine trials. Advised on community engagement issues, fund raising and capacity development |
| Description | Chairperson SARS-CoV2/COVID-19 Laboratory Quality Assurance Committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | This committee has led to policies and practice on which tests to use, which laboratories to test for SARS-CoV-2 and provided testing panels. |
| Description | Chairperson, National Task Force for Laboratory Polio Containment |
| Geographic Reach | Africa |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Guidance on proper disposal of used vaccine vials |
| Description | Guidance on HIV hot spots and direction of transmission |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | This has helped in understanding which are the hot spots for HIV, for example we showed that though fishing communities have high HIV prevalence they are not the main source of HIV transmissions in the general population. This has influenced on how prevention is done to spread beyond concentrating on the fishing communities. This has led to better HIV prevention in Uganda |
| Description | Guidance to Ministry on which COVID-19 antigen, antibody and PCR kits to use |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | This has guided on the tests to use during the COVID-19 pandemic and guided private sector which kits to import |
| Description | I chair the HIV drug resistance Technical working group |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | The work of this committee and the studies it manages have led to changes in HIV treatment guidelines |
| Description | Information on the Anthrax outbreak in Southwestern Uganda |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | When it was confirmed that the strange disease that has killed people was anthrax better management of patients were instituted |
| Description | Member WHO Pathogen prioritization, Retrovirology group 2023 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Member, National Measles Verification Comiitee |
| Geographic Reach | Africa |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | follow-up of outbreaks, discussoion of outbreak response, preparation of WHO country report, |
| Description | Participated in Health Research Priority Ranking Survey towards the Essential National Health Research Agenda |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Still ongoing, knowledge and information is being gathered |
| Description | Provided information on Ebola Sudan outbreak that guided vaccinations |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | There was introduction of vaccines for Ebola Sudan instead of Ebola Zaire and information that the therapeutics for Ebola Zaire would not be effective during this outbreak |
| Description | SARSCoV2 variants in Uganda for proper vaccination planning |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | This work has guided on the selection of vaccines for SARSCoV2 |
| Description | Through membership and provision of advice as a member of the WHO National Measles Verification Committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Better coordination of outbreak response, identification of hotspots for enhanced intervention, updates to the minister of health |
| Description | Through membership and provision of advice to government as a member of the National Vaccine Development Advisory Committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | better understanding of the contribution of research to national development |
| Description | Through memership and provision of advice as a member of the WHO National Task Force for laboratory containment of Wild type Poliovirus |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Safety and biosecurity practices emphasised and trainings provided |
| Description | Understanding the cirsulating HIV strains in Uganda |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | By describing and providing information on the circulating HIV subtypes in Uganda, this information is used in HIV vaccine design and treatment. The vaccine, monoclonal antibodies and drugs developed have to be relevant in terns of the HIV strains they target. We are seeing an increase in the proportion of HIV recombinant viruses in Uganda. |
| Guideline Title | The revised 2018 HIV treatment guidelines |
| Description | Use of Integrase strand inhibitors (Dolutegravir) as first line due to high Pre-Treatment HIVDR to NNRTIs in the country. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Uganda and other countries where HIV pre-treatment drug resistance is above 10%, have adopted Dolutegragir ased regimens as the preferred first line ART regimen in women >50 years, adolescent and adult men; and as an alternative second line in the above eligible groups. |
| Description | A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M in African children living with HIV (VAC092) |
| Amount | € 1,095,385 (EUR) |
| Organisation | Serum Institute of India |
| Sector | Private |
| Country | India |
| Start | 05/2022 |
| End | 06/2024 |
| Description | A Randomized, Observer-Blind, Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults (COVAC-003) |
| Amount | $604,538 (USD) |
| Organisation | University of Saskatchewan |
| Sector | Academic/University |
| Country | Canada |
| Start | 12/2021 |
| End | 03/2024 |
| Description | A combination efficacy study in Africa of two DNA-MVA & DNA-protein/adjuvant HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP); "PrEPVacc |
| Amount | € 15,000,000 (EUR) |
| Funding ID | S-RIALoI2015-555 |
| Organisation | Sixth Framework Programme (FP6) |
| Department | European and Developing Countries Clinical Trials Partnership |
| Sector | Public |
| Country | Netherlands |
| Start | 07/2018 |
| End | 07/2024 |
| Description | Analyzing HIV-1 Reservoir Kinetics, and Host Immune Interactions among non-B subtypes |
| Amount | £680,000 (GBP) |
| Organisation | Francis Crick Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 04/2028 |
| Description | CEPI-CLN: Development and qualification of of Ebola SUDV and Marburg immunogenicity assays (ELISA, ELISpot and Neutralisation) |
| Amount | $1,200,000 (USD) |
| Organisation | Coalition for Epidemic Preparedness Innovations |
| Sector | Learned Society |
| Country | Norway |
| Start | 05/2024 |
| End | 06/2026 |
| Description | COVID-19 vaccine effectiveness and variants in Uganda: a test- negative case-control study with genetic sequencing (COVVAR) |
| Amount | $509,268 (USD) |
| Organisation | World Health Organization Regional Office for Africa |
| Sector | Public |
| Country | Congo |
| Start | 03/2023 |
| End | 03/2023 |
| Description | Collaboratory Pilot: SARS-CoV-2 Breakthroughs |
| Amount | $250,000 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2024 |
| End | 11/2025 |
| Description | Collaboratory Platform: Strategies to elicit broadly neutralising antibodies |
| Amount | $150,000 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2024 |
| End | 11/2025 |
| Description | Collaboratory Platform: Unlocking SARS-CoV-2 Immunity for Pan-Coronavirus Immune Therapies. |
| Amount | $150,000 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2024 |
| End | 11/2025 |
| Description | Differences in Epidemiology and antiViral Immune responses across an African NeTwork (DEVIANT). A collbaoration across all GIISER sites |
| Amount | $4,000,000 (USD) |
| Organisation | Science for Africa Foundation |
| Sector | Charity/Non Profit |
| Country | Kenya |
| Start | |
| Description | Global Immunology and Immune Sequencing for Epidemic Response (GIISER) |
| Amount | $299,997 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2021 |
| End | 08/2024 |
| Description | HIV-PANGEA II : renewal of Phylogenetics and Networks for Generalised HIV |
| Amount | $3,123,714 (USD) |
| Funding ID | INV-007573 |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2017 |
| End | 10/2022 |
| Description | IAVI ADVANCE: Harmonising NGS sequencing platforms for transmitted viral identification, recombination and signature analyses for contemporary HIV-1 viruses |
| Amount | $370,000 (USD) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 01/2023 |
| End | 12/2024 |
| Description | IAVI funded through USAID |
| Amount | $100,000,000 (USD) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 06/2016 |
| End | 06/2021 |
| Description | Immune modulation with pomalidomide in advanced Kaposi sarcoma (IMPALA-KS): a multicentre, multinational randomised controlled non-inferiority trial of oral pomalidomide versus standard intravenous liposomal doxorubicin in resource limited settings |
| Amount | $3,000,000 (AUD) |
| Organisation | National Health and Medical Research Council |
| Sector | Public |
| Country | Australia |
| Start | 06/2025 |
| End | 06/2030 |
| Description | Implementing oral and long acting Pre-exposure prophylaxis in mobile men in Sub-Saharan Africa (MOBILE MEN) |
| Amount | € 4,779,208 (EUR) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 11/2023 |
| End | 11/2026 |
| Description | Improving HIV Control in Africa with Long-Acting Antivirals (IMPALA) |
| Amount | $8,046,347 (USD) |
| Organisation | Johnson & Johnson |
| Sector | Private |
| Country | United States |
| Start | 08/2022 |
| End | 12/2025 |
| Description | Investigator Initiated Research: Assessment of Suitability of biomedical prevention products against contemporary strains of HIV-1 in India and Uganda |
| Amount | $180,514 (USD) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 11/2023 |
| End | 04/2026 |
| Description | Investigator Initiated Research: Exploration of the virologic characteristics of recently transmitted viruses in Uganda and Kenya |
| Amount | $150,907 (USD) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 01/2021 |
| End | 12/2024 |
| Description | Investigator Initiated Research: Using Next Generation Sequencing methodology to improve HIV-1 incidence estimation |
| Amount | $75,000 (USD) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 01/2023 |
| End | 12/2024 |
| Description | Seeking predictors of vaccine efficacy: identifying correlates of protection to support vaccine development Identifying Rift Valley Fever correlates of protection to support vaccine development |
| Amount | £5,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2024 |
| End | 08/2029 |
| Description | Seeking predictors of vaccine efficacy: identifying correlates of protection to support vaccine development PROTECT: Research on Correlates of Protection to generate Effective Filovirus countermeasures with University of Oxford |
| Amount | £5,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2024 |
| End | 08/2029 |
| Description | Seeking predictors of vaccine efficacy: identifying correlates of protection to support vaccine development. VacICoP: Chimpanzee Adenovirus Type 3-Vectored Marburg Glycoprotein (GP)-Expressing Vaccine (ChAd3-MARV)-Induced Correlates of Protection |
| Amount | £5,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2024 |
| End | 08/2029 |
| Description | Viral Surveillance and Discovery in Uganda. Abbott Diagnostics |
| Amount | $821,733 (USD) |
| Organisation | Abbott |
| Sector | Private |
| Country | United States |
| Start | 03/2022 |
| End | 03/2024 |
| Title | 10x Genomics Technology for underpinning molecular mechanisms for immune responses (gremlins, BCR and TCR) |
| Description | Characterising BCR and TCR determinants of immunity |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | local genetic determinants of immunity |
| Title | Focus Reduction Neutralisation test (2025) |
| Description | Procedures for assessing neutralisation of Mpox |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2025 |
| Provided To Others? | No |
| Impact | Capacity for new functional assays on Mpox Immunology |
| Title | In-house ELISA |
| Description | An in-house ELISA for the detection and quantification of antibodies in serum. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Bioprotocol publication. |
| URL | https://bio-protocol.org/en/bpdetail?id=4905&type=0 |
| Title | Single Cell Technologies |
| Description | 10X technology and single cell sorting, BCR determinants |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | Development and characterisation of monoclonal antibodies |
| Title | Data for: Changes in self-reported risky sexual behaviour indicators among adults receiving regular risk reduction counselling and optional initiation of pre-exposure prophylaxis in an HIV vaccine preparedness study in Masaka, Uganda |
| Description | A quantitative dataset collected as part of an on-going HIV vaccine preparedness study "The PrEPVacc Registration Cohort". It contains information on demographic, HIV risk behavioural characteristics and PrEP uptake among participants. Responses cover participants from the Masaka registration cohort who completed at least one year of follow-up in the cohort. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Not known |
| URL | https://datacompass.lshtm.ac.uk/id/eprint/3403 |
| Title | Data set for: "Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018-2022 HIV vaccine preparedness cohort in Masaka, Uganda" |
| Description | A quantitative data set produced as part of the PrEPVacc Registration Cohort, a study to prepare a population of HIV negative individuals at risk of acquiring HIV for possible participation in the PrEPVacc HIV vaccine efficacy trial. Data was collected between July 2018 and December 2022 from a registration cohort located in Masaka, Uganda. Variables cover HIV incidence, and associated demographic and behavioural factors. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2025 |
| Provided To Others? | Yes |
| Impact | Not known |
| URL | https://datacompass.lshtm.ac.uk/id/eprint/4608 |
| Title | Data set for: Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: the PrEPVacc trial |
| Description | A compiled pseudo-anonymised quantitative dataset collected as part of the PrEPVacc registration cohort and trial. The registration cohort was set up to prepare a population of HIV negative individuals at risk of acquiring HIV for possible participation in the PrEPVacc phase IIB HIV prophylactic vaccine and pre-exposure prophylaxis trial. There are two components to this dataset, firstly the cohort dataset that was used to develop a regression model predicting HIV incidence. Secondly, a trial dataset with the participant characteristics that could be entered in the model and utilised for prediction of HIV incidence that could have occurred if participants in the active-controlled PrEP trial component had never been dispensed PrEP. The PrEPVacc trial was conducted at four study sites in Tanzania (2 sites), South Africa, and Uganda. This dataset is as of 31 Jan 2024. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Not known |
| URL | https://datacompass.lshtm.ac.uk/id/eprint/4435 |
| Title | Data set for: Contraceptive use, prevalence and incidence of pregnancy and associated factors among women participating in a vaccine preparedness cohort study in Masaka, Uganda, a retrospective secondary analysis |
| Description | A quantitative dataset collected as part of an HIV vaccine trial preparedness study "The PrEPVacc Registration Cohort". The study was set up at sites in Tanzania, Mozambique, South Africa, and Uganda to prepare a population of HIV negative individuals at risk of acquiring HIV for possible participation in the PrEPVacc HIV vaccine efficacy trial. In Uganda, the study is conducted at the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit's clinical research site in Masaka city, Masaka district. This data set only includes data from the Masaka registration cohort collected between July 2018 and October 2022. It contains information on demographic, HIV risk behavioural characteristics, contraception, and urine pregnancy test results. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Not known |
| URL | https://datacompass.lshtm.ac.uk/id/eprint/4212 |
| Title | Medical survey data to monitor trends in HIV epidemiology and assess the prevalence of Non-Communicable Diseases (NCDs) and associated factors in Central Uganda |
| Description | An anonymized dataset containing survey responses of 6808 adults, aged 16 or more years, in the General Population Cohort of Central Uganda. Longitudinal data was collected through bi-annual medical surveys to monitor trends in HIV epidemiology, and assess the prevalence of Non-Communicable Diseases (NCDs) and associated factors. Variables include socio-demographic information, update of HPV Vaccination, knowledge of HIV, alcohol consumption, tobacco use, COVID-19 symptoms, the effect of COVID-19 lockdown on health service outcomes, anthropometric measurements, and HIV status. Files will be made available via https://apps.mrcuganda.org/mrcdatavisibility/Home/ |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Unknown |
| URL | https://datacompass.lshtm.ac.uk/id/eprint/3702 |
| Title | Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda |
| Description | Intimate partner violence (IPV) poses a public health burden, yet few studies have assessed co-existence of physical, emotional, and sexual IPV among adolescents. We assessed recent IPV victimization and associated factors and described IPV patterns and perpetrators among young people from urban slums in Kampala, Uganda. We conducted a prospective cohort study among 14 to 19-year-old individuals enrolled from March 2019 to March 2020 and followed quarterly for 12 months. We collected data on socio-demographics, sexual behavior, and substance use through interviews. Recent IPV victimization was documented at all visits if a participant reported experiencing physical, emotional, and/or sexual IPV in the past 3 months. Baseline factors associated with recent IPV victimization were determined using multivariable logistic regression. We enrolled 490 adolescents (60.6% female) with median age 18 years (Interquartile range (IQR) 17-18 years), 91.0% had less than secondary level education. Females mainly engaged in sex work (17.5%) and selling fruits/snacks (9.1%) while males commonly earned from sale of metal scrap or plastic waste (28.5%), 41% reported =10 life-time sexual partners, 16.1% were high-risk alcohol drinkers and 34.9% used illicit drugs in the past 3 months. Overall, 27.8% reported recent IPV victimization (20.0% females) with emotional IPV being common (17.8%). At baseline, recent IPV victimization was associated with high-risk alcohol consumption (adjusted odds ratio [aOR] 2.57; 95% confidence interval [CI] [1.44, 4.58]), reported paid sex in the past 3 months (aOR 1.82; [1.02, 3.22]) and being separated (aOR 2.47; [1.29, 4.73]). Recent IPV victimization declined from baseline to month 9 and increased at month 12 visits which coincided with the COVID-19 pandemic. IPV victimization is high among young people living in urban slums with emotional IPV being prevalent. IPV interventions are needed and should also address excessive alcohol consumption. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Unknown |
| URL | https://sage.figshare.com/collections/Prevalence_Perpetrators_and_Factors_Associated_With_Intimate_P... |
| Title | Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda |
| Description | Intimate partner violence (IPV) poses a public health burden, yet few studies have assessed co-existence of physical, emotional, and sexual IPV among adolescents. We assessed recent IPV victimization and associated factors and described IPV patterns and perpetrators among young people from urban slums in Kampala, Uganda. We conducted a prospective cohort study among 14 to 19-year-old individuals enrolled from March 2019 to March 2020 and followed quarterly for 12 months. We collected data on socio-demographics, sexual behavior, and substance use through interviews. Recent IPV victimization was documented at all visits if a participant reported experiencing physical, emotional, and/or sexual IPV in the past 3 months. Baseline factors associated with recent IPV victimization were determined using multivariable logistic regression. We enrolled 490 adolescents (60.6% female) with median age 18 years (Interquartile range (IQR) 17-18 years), 91.0% had less than secondary level education. Females mainly engaged in sex work (17.5%) and selling fruits/snacks (9.1%) while males commonly earned from sale of metal scrap or plastic waste (28.5%), 41% reported =10 life-time sexual partners, 16.1% were high-risk alcohol drinkers and 34.9% used illicit drugs in the past 3 months. Overall, 27.8% reported recent IPV victimization (20.0% females) with emotional IPV being common (17.8%). At baseline, recent IPV victimization was associated with high-risk alcohol consumption (adjusted odds ratio [aOR] 2.57; 95% confidence interval [CI] [1.44, 4.58]), reported paid sex in the past 3 months (aOR 1.82; [1.02, 3.22]) and being separated (aOR 2.47; [1.29, 4.73]). Recent IPV victimization declined from baseline to month 9 and increased at month 12 visits which coincided with the COVID-19 pandemic. IPV victimization is high among young people living in urban slums with emotional IPV being prevalent. IPV interventions are needed and should also address excessive alcohol consumption. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Unknown |
| URL | https://sage.figshare.com/collections/Prevalence_Perpetrators_and_Factors_Associated_With_Intimate_P... |
| Title | sj-docx-1-jiv-10.1177_08862605231155128 - Supplemental material for Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda |
| Description | Supplemental material, sj-docx-1-jiv-10.1177_08862605231155128 for Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda by Yunia Mayanja, Onesmus Kamacooko, Jane Frances Lunkuse, Nambusi Kyegombe and Eugene Ruzagira in Journal of Interpersonal Violence |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Unknown |
| URL | https://sage.figshare.com/articles/journal_contribution/sj-docx-1-jiv-10_1177_08862605231155128_Supp... |
| Title | sj-docx-1-jiv-10.1177_08862605231155128 - Supplemental material for Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda |
| Description | Supplemental material, sj-docx-1-jiv-10.1177_08862605231155128 for Prevalence, Perpetrators, and Factors Associated With Intimate Partner Violence Among Adolescents Living in Urban Slums of Kampala, Uganda by Yunia Mayanja, Onesmus Kamacooko, Jane Frances Lunkuse, Nambusi Kyegombe and Eugene Ruzagira in Journal of Interpersonal Violence |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Unknown |
| URL | https://sage.figshare.com/articles/journal_contribution/sj-docx-1-jiv-10_1177_08862605231155128_Supp... |
| Description | Analyzing HIV-1 Reservoir Kinetics, and Host Immune Interactions among non-B subtypes |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provide samples and infrastructure for laboratory assays |
| Collaborator Contribution | Mentorship during the research project |
| Impact | Research recently commenced |
| Start Year | 2024 |
| Description | Assessment of suitability of biomedical prevention products against the contemporary strains of HIV-1 in India and Uganda |
| Organisation | Institute of Bio-Resources and Sustainable Development |
| Country | India |
| Sector | Public |
| PI Contribution | Collaborative project to characterize contemporary HIV-1 viruses from Uganda |
| Collaborator Contribution | Collaborative project to characterize contemporary HIV-1 viruses from India |
| Impact | Research has recently started |
| Start Year | 2023 |
| Description | Assessment of suitability of biomedical prevention products against the contemporary strains of HIV-1 in India and Uganda |
| Organisation | Translational Health Science And Technology Institute |
| Country | India |
| Sector | Public |
| PI Contribution | Collaborative project to characterize contemporary HIV-1 viruses from Uganda |
| Collaborator Contribution | Collaborative project to characterize contemporary HIV-1 viruses from India |
| Impact | Research has recently started |
| Start Year | 2023 |
| Description | CHADOX RVF trial |
| Organisation | Uganda Virus Research Institute |
| Country | Uganda |
| Sector | Public |
| PI Contribution | Specimen collection and storage, running trial end point assays, |
| Collaborator Contribution | Technical support |
| Impact | Capacity building for endpoint immunogenicity |
| Start Year | 2023 |
| Description | Capacity building for metagenomic Next Generation Sequencing (mNGS) infrastructure |
| Organisation | Medical Research Council (MRC) |
| Department | MRC/UVRI and LSHTM Research Unit Uganda |
| Country | Uganda |
| Sector | Academic/University |
| PI Contribution | MRC Capital bids supported the setting up of an automated library preparation system for metagenomics next generation sequencing applications. |
| Collaborator Contribution | Funders |
| Impact | Facilitates more efficient downstream Next Generation Sequencing applications for pathogen genomics projects. |
| Start Year | 2023 |
| Description | Collaboration with Ministry of Health |
| Organisation | Ministry of Health, Uganda |
| Country | Uganda |
| Sector | Public |
| PI Contribution | Generation of SARS CoV2 sequence data, policy on vaccine usage |
| Collaborator Contribution | Generation of SARS CoV2 sequence data, policy on vaccine usage |
| Impact | Publications, policy |
| Start Year | 2023 |
| Description | Collaborationwith the Ministry of Health on Research on emerging and re-emeging infections |
| Organisation | Ministry of Health, Uganda |
| Country | Uganda |
| Sector | Public |
| PI Contribution | We are conducting surveillance studies for new and re-ermerging viruses. We look for funding, collaborations and conduct some of the studies locally |
| Collaborator Contribution | The Ministry of Health Departments offer the environment to work in different surveillance sites and some epidemiological expertise |
| Impact | Publications, policies, and valuable samples |
| Start Year | 2016 |
| Description | Cyclic Acquired HIV Drug Resistance Surveillance in Uganda |
| Organisation | Centers for Disease Control and Prevention (CDC) |
| Country | United States |
| Sector | Public |
| PI Contribution | HIV drug resistance genotyping of children and adults on dolutegravir based drug regimens. |
| Collaborator Contribution | Contributions towards protocol development. |
| Impact | Study has found from preliminary results higher level HIV drug resistance to DTG based regimens in persons below 15 years relative to those older than 15 years. |
| Start Year | 2023 |
| Description | Exploration of the Virologic characteristics of Recently transmitted HIV-1 viruses in Uganda and Kenya |
| Organisation | Kenya AIDS Vaccine Initiative (KAVI) |
| Country | Kenya |
| Sector | Academic/University |
| PI Contribution | - Generated transmitted founder viruses using Single Genome amplification - Conducted Signature analyses - Phenotypic characterization of transmitted HIV-1 viruses (co-receptor usage) - Validation of the Oxford Nanopore platform for identification of transmitted viruses |
| Collaborator Contribution | - KAVI provided samples from the acute protocol B cohort from Kenya |
| Impact | - Three manuscripts in-pipeline - Virology, Bioinformatics, Immunology |
| Start Year | 2021 |
| Description | Global Immunology and Immune Sequencing for Epidemic Response (GIISER) |
| Organisation | Bill and Melinda Gates Foundation |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Profiling the immune response to COVID-19 in Uganda, and immune response to COVID-19 vaccines, Humoral (binding and Neutralisation)assays, Coference presentations, publications, |
| Collaborator Contribution | Access to diverse collaborative platforms and institutions, sharing of an extensive array of research biological reagents, including plasmids for protein expression and Psudovirus production. Acquisition of state-of-the-art equipment and technologies, including 10x technology, with a focus on monoclonal antibody discovery, structural biology, systems immunology, peptide arrays, and single-cell methodologies to unravel the molecular underpinnings of immune responses against viral infections. |
| Impact | Technology transfer, capacity building, scientific literature, reagent transfer, assay transfer, Peer reviewed publications |
| Start Year | 2023 |
| Description | HIV Virus Surveillance with IAVI and NICD South Africa |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | Running immunology assays, (testing fusion peptide supersite on historical and contemporary HIV-viruses) |
| Collaborator Contribution | Funding, trainings , partneships and collaborations with other African collborators including NICD in South Africa, Kilifi Kenya |
| Impact | Capacity building, technology transfer, acquisition of immunology equipment (readers, centrifuges,, freezers) |
| Start Year | 2023 |
| Description | Harmonising NGS Sequencing platforms for T/F identification, Recombination and signature analysis for contemporary viruses |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | Genotypic and Phenotypic characterization of transmitted viruses |
| Collaborator Contribution | Financial resources and coordination |
| Impact | -HIV-1 characterization for vaccine development - Enhanced Bioinformatics skilling |
| Start Year | 2023 |
| Description | IAVI Clinical Trial and Laboratory Program for 2016-2017 |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | We provide cohorts, epidemiological, clinical and laboratory expertise to this partnership |
| Collaborator Contribution | They provide funds, capacity building and networking with other vaccine Research and Development partners |
| Impact | Publications, training and laboratory infrastructure |
| Start Year | 2017 |
| Description | IMMPROVE (Immune memory and mechanisms of protection from Vaccines |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-Investigator |
| Collaborator Contribution | Provision of capacity building and pump priming grants |
| Impact | Pump priming grants |
| Start Year | 2024 |
| Description | Imperial College London, collaboration for training on SARS-CoV-2 mAb discovery and characterisation |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | running end point assays for PrEPVacc and COVAC2 trials |
| Collaborator Contribution | Study monitoring oversight, analyses |
| Impact | Capacity building for endpoint immunogenicity |
| Start Year | 2023 |
| Description | Inactivated COVID-19 Vaccine Development Project; pilot studies to optimise preclinical assessment at COVAB, Makerere University |
| Organisation | Government of Uganda |
| Country | Uganda |
| Sector | Public |
| PI Contribution | Development of an Inactivated COVID-19 vaccine, running of immunology assays, COVID-19 surveillance. |
| Collaborator Contribution | Funding, training, capacity building and acquisition of state-of-the-art equipment and technologies, including an AktaPure purifier, Luminex, BD Cell sorter, and 10x technology to support monoclonal antibody discovery. |
| Impact | Development of an Inactivated COVID-19 vaccine, running of immunology assays, vaccine production equipment. |
| Start Year | 2023 |
| Description | Kings College London (Monoclonal Antibody Discovery) |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | generation of scientific data, scientific literature |
| Collaborator Contribution | Technology transfer, assay and reagent transfer, capacity building. |
| Impact | monoclonal antibody discovery pipeline, cell sorting capacity transfer, assay transfer. |
| Start Year | 2023 |
| Description | LaJolla Institute for Immunology, Collaborations for mAb discovery and characterisation for Ebola Sudan and Marburg |
| Organisation | La Jolla Institute for Immunology |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Assay development and assessment of longitudinal specimens profiling |
| Collaborator Contribution | Biological reagents, plasmids, pseudoviruses and antigenic probes |
| Impact | Assays optimisation for neutralisation |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | Desmond Tutu HIV Foundation |
| Country | South Africa |
| Sector | Charity/Non Profit |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | Public Assistance - Hospitals of Paris |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | University of KwaZulu-Natal |
| Department | KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) |
| Country | South Africa |
| Sector | Charity/Non Profit |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | MOBILE MEN |
| Organisation | Wits Health Consortium |
| Country | South Africa |
| Sector | Private |
| PI Contribution | Trial coordination and sponsorship, recruitment of study participants, Study monitoring |
| Collaborator Contribution | Expertise in health economics and implementation science, Financial management and reporting, recruitment of study participants |
| Impact | None yet |
| Start Year | 2023 |
| Description | Metagenomics analyses with Glasgow University |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have provided specimens. We have received sequences generated at Glasgow for analysis at UVRI. We have participated in writing of new research grants. We have worked with the team to present data to the research community and to the local communities in West Nile where a new virus was isolated |
| Collaborator Contribution | They have trained our staff in metagenomics, and contributed to the transfer of technology. Three of our staff have visited Glasgow and a team led by Dr Emma Thompson has also visited us. We are together writing other research grants |
| Impact | In the process of looking for Zika virus, we have also identified other viruses including Le Dantec Rhabdovirus. Metagenomic analysis of the acute plasma RNA revealed a contiguous sequence of 11,423 nucleotides that had a 94% identity with a 1965 LDV strain isolated from a Senegalese girl (DakHD763 strain, KM205006) by phylogenetic analysis. The metagenomics sequence was confirmed by PCR and Sanger sequencing of a 5'-half genome fragment. We have also identified a new virus named Adumi virus, from a girl in West Nile region |
| Start Year | 2015 |
| Description | Molecular, Serological and Immunological Characterisation of Clade 1b Mpox to Improve Diagnostics for Local and Regional Epidemic Response |
| Organisation | Coalition for Epidemic Preparedness Innovations |
| Country | Norway |
| Sector | Learned Society |
| PI Contribution | Lead Investigator |
| Collaborator Contribution | Entebbe Hospital, collaborator CEPI, Funder |
| Impact | Determined the Antmicrobacterial resistance patterns |
| Start Year | 2025 |
| Description | National Institute on Communicable Diseases (NICD), South Africa on HIV-1 virus Surveillance to determine if new and older strains of transmitted HIV-1 are still sensitive to available broadly neutralising antibodies (bnAbs) |
| Organisation | International AIDS Vaccine Initiative (IAVI) |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | Scientific direction and undertaking the research |
| Collaborator Contribution | Coordination, trainings |
| Impact | Data, knowledge, presentation, manuscripts are being written |
| Start Year | 2023 |
| Description | PANGEA |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a collaboration on phylogenetic analysis funded by the BMGF. It has led to capacity building in bioinformatics and understanding HIV transmission nets |
| Collaborator Contribution | Capacity building and networking |
| Impact | Publications and generation of analysis pipelines |
| Start Year | 2014 |
| Description | PANGEA Consortium Bridge funding |
| Organisation | Bill and Melinda Gates Foundation |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | 1. Investigating the Molecular Epidemiology of HIV in Ugandan populations 2. Reconstruction of HIV transmission networks with the aim of generating information that is intended to guide targeted interventions in key populations |
| Collaborator Contribution | 1. Funding 2. Translating results into information that is actionable to prevention through influencing policy. |
| Impact | 1. Source-sink analysis revealed that the HIV high-risk fishing communities were sinks and not sources of HIV from the general population 2. Men older than 25 years of age contribute majority of new HIV infections. |
| Start Year | 2023 |
| Description | PrEPVacc |
| Organisation | European Union |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | Supervision of sites lab functions, Central repository across all sites, Leading on conducting end point assays (binding antibody ELISA), specimen collection and processing. |
| Collaborator Contribution | Funding and partnerships across African collaborations (Tanzania, South Africa and Mozambique) |
| Impact | Capacity building, technology transfer, acquisition of immunology equipment, Publications |
| Start Year | 2023 |
| Description | Real-time Analysis for the Phylogenetic Interrogation of Drug-resistant HIV clusters (RAPID-HIV) |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Phylogenetic and network analysis of HIV drug resistant clusters in different populations in Uganda. |
| Collaborator Contribution | Contributions towards protocol development. |
| Impact | Information generated on where cluster of HIV drug resistance are likely to emerge in the Ugandan populations that is key in guiding patient care and policy making on the roll-out to ART. |
| Start Year | 2021 |
| Description | SARS-COV-2 Surveillance in Uganda. |
| Organisation | Africa Centres For Disease Control And Prevention |
| Country | Ethiopia |
| Sector | Charity/Non Profit |
| PI Contribution | 1.Genomic sequencing of clinical samples during the COVID-19 pandemic. 2. Providing SARS-CoV-2 genomic surveillance in Uganda |
| Collaborator Contribution | Funding |
| Impact | 1. Generated data on circulating SARS-CoV-2 variants in Uganda that guided COVID-19 response. 2. Deposited SARS-CoV-2 genomes in the GISAID database |
| Start Year | 2021 |
| Description | SMART Trial Mpox Clinical Diagnostics and Sequencing |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Our team will receive and test for PCR for all the specimens for study participants from the SMART Study, currently being conducted in the DRC. Will also conduct whole genome viral sequencing for all positive samples identified through this testing. |
| Collaborator Contribution | This study aims to determine if post-exposure administration with a single dose of Modified Vaccinia Bavarian Nordic vaccine can reduce RT-PCR confirmed mpox and symptom severity in household contacts. |
| Impact | 1. Capacity building 2. Collaboration is multi-disciplinary involving Molecular Virology, genomics, bioinformatics, social sciences, etc |
| Start Year | 2024 |
| Description | Sabin Vaccine Institute, Collaborations on vaccine development and evaluation |
| Organisation | SABIN Vaccine Institute |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Joint grant applications |
| Collaborator Contribution | Joint grant applications for correlates of protection studies |
| Impact | joint grant applications, sharing of SOPs |
| Start Year | 2023 |
| Description | Sabin Vaccine Institute, Collaborations on vaccine development and evaluation |
| Organisation | SABIN Vaccine Institute |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Joint grant applications |
| Collaborator Contribution | Joint grant applications for correlates of protection studies |
| Impact | joint grant applications, sharing of SOPs |
| Start Year | 2023 |
| Description | Studies of KSHV and EBV in Uganda and Kenya |
| Organisation | University of Colorado Denver |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | I am the Principal Investigator. Colleagues at University of Colorado are intellectual partners and provid immunological support |
| Collaborator Contribution | Partners |
| Impact | Publications |
| Start Year | 2019 |
| Description | Studies of KSHV in Uganda |
| Organisation | National Institutes of Health (NIH) |
| Department | National Cancer Institute (NCI) |
| Country | United States |
| Sector | Public |
| PI Contribution | I am the Principal Investigator. The National Cancer Institute is a partner organization, providing laboratory support. |
| Collaborator Contribution | Intellectual and laboratory support. |
| Impact | Publications |
| Start Year | 2009 |
| Description | Superinfection studies |
| Organisation | Johns Hopkins University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision of specimens for testing of our samples for superinfection. Provision of other clinical and epidemiological data |
| Collaborator Contribution | Testing of samples for superinfection using the 454 deep sequencing |
| Impact | Data has been generated on the frequency of HIV superinfection in one of our high risk cohorts. Training of our in data analyses |
| Start Year | 2014 |
| Description | UVRI CEPI/CLN (Develoment and optimisation of assays to support vaccine development |
| Organisation | Coalition for Epidemic Preparedness Innovations |
| Country | Norway |
| Sector | Learned Society |
| PI Contribution | Lead Immunologist on Ebola, Marburg and Mpox Immunology protocols |
| Collaborator Contribution | funding and linkages |
| Impact | Assay development and reagent preparation |
| Start Year | 2024 |
| Description | Use of HIV full length sequencing to characterise HIV epidemics and evaluate interventions |
| Organisation | University College London |
| Department | UCL Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We provide specimens including clinical and epidemiological data. We also participate in the analysis of data |
| Collaborator Contribution | They provide funds, sequencing of the samples and training in the analyses of large sequence data |
| Impact | Conference Abstracts, paper manuscripts, we have also started analysing of near full length sequencing of HIV sequences within our Uganda Medical Informatics Centre |
| Start Year | 2014 |
| Description | Using Next Generation Sequencing methodology to improve HIV-1 incidence estimation |
| Organisation | Ministry of Health, Uganda |
| Country | Uganda |
| Sector | Public |
| PI Contribution | Full genome sequencing using the bulk pcr approach Bioinformatics analysis using Phylo tsi tool |
| Collaborator Contribution | Acute samples amounting to 150 previously tested with the the Asante kit |
| Impact | Research recently commenced |
| Start Year | 2023 |
| Description | VacICop (Correlates of Protection from Marburg Virus Disease) |
| Organisation | SABIN Vaccine Institute |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | I am a co-Investigator |
| Collaborator Contribution | Partners will implement some objectives of this grant, they will provide pump priming grants for students |
| Impact | Project starts in June 2025 |
| Start Year | 2025 |
| Description | VacICop (Correlates of Protection from Marburg Virus Disease) |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am a co-Investigator |
| Collaborator Contribution | Partners will implement some objectives of this grant, they will provide pump priming grants for students |
| Impact | Project starts in June 2025 |
| Start Year | 2025 |
| Description | Viral Pathogen Discovery: Mortuary Surveillance |
| Organisation | Abbott |
| Department | Abbott Diagnostics |
| Country | United States |
| Sector | Private |
| PI Contribution | Metagenomics Sequencing and genomic data analysis of autopsy samples. |
| Collaborator Contribution | Funding and capacity building in bioinformatics analyses. |
| Impact | Determining the etiology of diseases of unknown origin in suspected outbreaks in Uganda where deaths area involved. |
| Start Year | 2023 |
| Description | Viral Surveillance and Discovery in Uganda. Abbott Diagnostics |
| Organisation | Abbott |
| Department | Abbott Diagnostics |
| Country | United States |
| Sector | Private |
| PI Contribution | We perform surveillance for viral infections and discovery of new viruses using metagenomics. In the past we have been able to detect some outbreaks like anthrax using this approach |
| Collaborator Contribution | Abbott has provided funding, bioinformatics pipelines and opportunities for training. UVRI and the Ministry of Health the other partners have provided access to populations and samples, access to laboratories and equipment. |
| Impact | Averhoff F, Berg M, Rodgers M, Osmanov S, Luo X, Anderson M, Meyer T, Landay A, Gamkrelidze A, Kallas EG, Ciuoderis K, Hernandez JP, Henry JH, Osorio J, Lindo J, Deshommes J, Anzinger J, Manasa J, Alkashvili M, Souleyman M, Kaleebu P, Correa-Oliveira R, Solomon S, de Olivera T, Suputtamongkol Y, Cloherty G. The Abbott Pandemic Defense Coalition: a unique multi-sector approach adds to global pandemic preparedness efforts. Int J Infect Dis. 2022 Feb 5:S1201-9712(22)00080-7. doi: 10.1016/j.ijid.2022.02.001. |
| Start Year | 2022 |
| Description | Virological failure, antiretroviral resistance and genetic diversity among HIV-infected children following the introduction of integrase strand transfer inhibitors (INSTIs) in antiretroviral treatment protocols in Cameroon (RESIST-IN Project) |
| Organisation | Presidency of the Republic of Cameroon |
| Department | Centre Pasteur du Cameroun |
| Country | Cameroon |
| Sector | Public |
| PI Contribution | Training: Full genome sequencing to postdoctoral fellow using the Oxford nanopore and Sanger platforms to undertake Virological failure, antiretroviral resistance and genetic diversity studies in paedtric |
| Collaborator Contribution | Following the training, the Post doctoral fellow will set up the sequencing platform in Cameroon to under take Virological failure, antiretroviral resistance and genetic diversity among children. |
| Impact | Not outputs yet. Multidisciplinary: Virology and Bioinformatics |
| Start Year | 2025 |
| Title | Inactivated COVID-19 Vaccine |
| Description | An inactivated vaccine under pre-clinical trials funded by the Government of Uganda under the Ministry of Science and Technology. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | Vaccine development pipeline. Transient production of protein antigen. Establishment of a pipeline for inactivated vaccines |
| Title | SARS-CoV-2 Monoclonal Antibodies |
| Description | Therapeutic; Detection tools |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | Potent monoclonal antibodies against SARS-CoV-2 infection |
| Title | HIVseqDB: a portable resource for NGS and sample metadata integration for HIV-1 drug resistance analysis |
| Description | A portable, secure, and user-friendly resource for integrating NGS data with associated clinical and demographic data for analysis of HIV drug resistance. https://github.com/AlfredUg/HIVseqDB |
| Type Of Technology | Software |
| Year Produced | 2024 |
| Open Source License? | Yes |
| Impact | Freely available tools for NGS-based HIV-1 drug resistance analysis do not integrate these data. This poses a challenge in interpretation of the impact of low-abundance drug resistance mutations (LA-DRMs) mainly for resource-limited settings due to the shortage of bioinformatics expertise. To address this challenge, we developed an HIVseqDB, a portable, secure, and user-friendly resource for integrating NGS data with associated clinical and demographic data for analysis of HIV drug resistance |
| Description | A presentation to update members of parliament on progress with COVID-19 vaccine development |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | it was a presentation to update our national legislators on progress with our research and vaccine development |
| Year(s) Of Engagement Activity | 2023 |
| Description | ADVANCE Annual Principal Investigators' Meeting 2023. Updates on establishment and use of Viral inhibition assays for vaccine trials |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Annual general meeting to share updates and discuss way forward |
| Year(s) Of Engagement Activity | 2023 |
| Description | COVID-19 Variants and Immunology, Insights from Population Responses to COVID-19 Infection and Vaccination |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | visibility and attracting new partnerships |
| Year(s) Of Engagement Activity | 2025 |
| Description | COVID-19 vaccine effectiveness and variants in Uganda |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Over 50 researchers attended WHO sponsored meeting on COVID-19 Vaccine Effectiveness studies in Africa and SE Asia. Presented updates on the study in Uganda |
| Year(s) Of Engagement Activity | 2023 |
| Description | CREATE Fellows annual symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | HIV Drug Resistance surveillance in Uganda |
| Year(s) Of Engagement Activity | 2024 |
| Description | CROI 2024, 3-6 March 2024; Distinct Absence of Post-Boost S-IgG Surge in Sub-Saharan African COVID-19 Vaccinee Responses, Jennifer Serwanga, *, Violet Ankunda, Joseph Ssebwana Katende, Jackson Sembera, Laban Kato, Gerald Kevin Oluka, Claire Baine, and Pontiano Kaleebu, on behalf of the COVID-19 Immunoprofiling Team, |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference to share updates on HIV and SARS-CoV-2 research |
| Year(s) Of Engagement Activity | 2024 |
| Description | CROI 2024, Distinct Absence of Post-Boost S-IgG Surge in Sub-Saharan African COVID-19 Vaccinee Responses; Jennifer Serwanga, *, Violet Ankunda, Joseph Ssebwana Katende, Jackson Sembera, Laban Kato, Gerald Kevin Oluka, Claire Baine, and Pontiano Kaleebu, on behalf of the COVID-19 Immunoprofiling Team, |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | To share scientific updates on progress with HIV and SARS-CoV-2 scientific research |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.croiconference.org |
| Description | Chairing the WHO National Task Force for Laboratory Containment of Wild Poliovirus meetings to discuss status of polio containment as part of the global eradication programme |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Review of safety and containment procedures for laboratories of interest |
| Year(s) Of Engagement Activity | 2023,2024 |
| Description | Distinct genetic markers linked to HIV-1 Transmitted/Founder viruses originating in East Africa |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | National symposium about HIV that involved several stake holders. Shared evidence from their research, experiences from HIV interventions, strategies and practices in prevention, treatment and overall management of HIV/AIDS. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Eleventh EDCTP Forum 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | HIV drug resistance in Uganda |
| Year(s) Of Engagement Activity | 2023 |
| Description | Estimating the Effectiveness of DetermineTM HIV Early Detect in detecting Acute HIV-1 Infection |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | This presentation was made to policy makers that included the Minister of Health to provide results of the evaluation of a kit that can detect early HIV infection |
| Year(s) Of Engagement Activity | 2025 |
| Description | Evaluation of the National HIV Testing Services Algorithm |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation to policy makers and other scientists on the outcome of the Evaluation of the National HIV Testing Services Algorithm |
| Year(s) Of Engagement Activity | 2024 |
| Description | Incidence of Unintended Pregnancy and Associated Factors among Adolescent Girls and Young Women at risk of HIV in Kampala, Uganda. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation sparked questions and discussions on possible further research |
| Year(s) Of Engagement Activity | 2023 |
| Description | Interview for STAT news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Increased interest in HIV vaccine research and coverage by smaller media houses |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.statnews.com/2023/12/06/aids-hiv-vaccine-fail-prepvacc-africa/ |
| Description | Interview for STAT news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Coverage by other media houses |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.statnews.com/2023/12/06/aids-hiv-vaccine-fail-prepvacc-africa/ |
| Description | Invited Presentation; BMGF, Grand Challenges Annual Meeting 2023 | Dakar, Senegal; Gates of change for country driven epidemic response: Insights from Uganda |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting to discuss updates on epidemic research |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://gcgh.grandchallenges.org/article/grand-challenges-annual-meeting-2023-be-held-dakar-senegal |
| Description | Invited Presentation; SOLIDARITY United in solidarity against filovirus threats Building research readiness for a future filovirus outbreak |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting to discuss epidemic preparedness |
| Year(s) Of Engagement Activity | 2024 |
| Description | Invited presentation, CEPI Tech Talk |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | We were invited to present to CEPI our current work on outbreak investigations and capacity and progress with immunosuirveillance. We were encouraged to apply for the CEPI-Welcome grant on correlates pot protection |
| Year(s) Of Engagement Activity | 2023 |
| Description | Media coverage - PrEPVacc vaccine trial results release at ICASA 2023 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | The PrEPVacc trial results presented at the ICASA conference (202) was covered by the Guardian news paper under the headline "HIV vaccine trial in Africa halted after disappointing initial results" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.theguardian.com/global-development/2023/dec/07/prepvacc-hiv-trial-africa-halted-after-di... |
| Description | Media coverage of PrEPVacc trial |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | CNN story on PrEPVacc trial under headline "A trial is underway that could be 'the last roll of the dice' for an HIV vaccine this decade" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://edition.cnn.com/2023/08/28/health/prepvacc-hiv-vaccine-trial-spc-scn-intl/index.html |
| Description | Mpox testing and genetic characterisation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation at Makerere University of Mpox testing and genetic characterisation |
| Year(s) Of Engagement Activity | 2024 |
| Description | Mpox testing and genetic characterisation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation at Makerere University of Mpox testing and genetic characterisation |
| Year(s) Of Engagement Activity | 2024 |
| Description | Mpox testing and genetic characterisation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation at Makerere University of Mpox testing and genetic characterisation |
| Year(s) Of Engagement Activity | 2024 |
| Description | Nation Television Uganda (NTV) interview on HIV Drug Resistance in Uganda |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Speaking on the current status of HIV drug resistance in Uganda and how it impacts on patient care in the country. |
| Year(s) Of Engagement Activity | 2023 |
| Description | National Science Week |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | A five day session to update the general public and stakeholders on the progress with preparations of an inactivated COVID-19 vaccine in Uganda |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://nsw.sti.go.ug |
| Description | PANGEA Consortium Annual meeting 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The goal of the PANGEA HIV consortium is to use phylogenetics to identify the populations that are most at risk of becoming infected with HIV and most at risk of passing on the virus. With a lot of data and publications generated over the years across multiple sites, the purpose of the meeting was to brainstorm how these results can be translated into policies that are actionable to HIV prevention. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Pandemic Science Conference; Coronavirus disease-19 induces moderate cytokine expressions among mild and asymptomatic individuals in Uganda; Kalyebi Arthur Watelo, Ankunda Violet, Ssali Ivan, Oluka Gerald Kevin, Obondo James Sande, Ben Gombe, The COVID-19 Immuno-profiling Team, Kaleebu Pontiano, Serwanga Jennifer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A conference to share updates on epidemic preparedness research |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://fitwise.eventsair.com/pandemic2023/ |
| Description | Panel discussion "How to speed up assay development" focusing on best practice, challenges and bottle necks and possible solutions. CEPI Face to Face meeting, Rome, 9-10 July 2024 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Closer collaborations with participating partners |
| Year(s) Of Engagement Activity | 2024 |
| Description | PrEPVacc Annual Investigators meeting, Zanzibar, 2004; Update on endpoint immunogenicity assays assessments |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussing progress and planning wayforwrd for the PrEPVacc Vaccine trial |
| Year(s) Of Engagement Activity | 2024 |
| Description | PrEPVacc: An in-depth look at the trial, and what's next |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Attended by close to 100 media practitioners and activists who asked lots of interesting questions |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://avac.org/blog/upcoming-webinars-and-workshops-you-wont-want-to-miss/ |
| Description | PrEPVacc: design, implementation, baseline results, and current status, Harare, Zimbabwe - ICASA 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The presentation sparked a lot of media interest and requests for interviews and was reported on by major news outlets including CNN, the Guardian, STAT news |
| Year(s) Of Engagement Activity | 2023 |
| Description | Presentation at the Gambia Unit anniversary |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I presented on the SARS CoV-2 variants in Uganda and evaluation of testing kits |
| Year(s) Of Engagement Activity | 2023 |
| Description | Presentation at the LSHTM week |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We presentation on the state of SARS CoV-2 at the LSHTM week |
| Year(s) Of Engagement Activity | 2021,2022,2023 |
| Description | Setting up a Research Museum: The UVRI Experience |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Setting up a Research Museum: The UVRI Experience. This was a presentation at an international conference on archives that was organized by Makerere University |
| Year(s) Of Engagement Activity | 2024 |
| Description | Spike-Directed IgG Elevation Correlates with Robust IgG Antibody Response Targeting the SARS-CoV-2 S2 Spike Subunit for Viral Immunity; Claire Baine, Jackson Sembera, Geoffrey Odoch, Maria Bafumba, Gerald Kevin Oluka, Violet Ankunda, Laban Kato, Joseph Ssebwana Katende, COVID-19 Immunoprofiling Team, Pontiano Kaleebu, Jennifer Serwanga |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | It was a scientific Immunology conference conference to share update on scientific progress in the field |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://iuis2023.org |
| Description | TV presentation on SARSCoV-2 variants in Uganda |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | I presented on the state of SARS CoV-2 in Uganda including the variants that exist |
| Year(s) Of Engagement Activity | 2021,2022,2023 |
| Description | Talk at the 5th European Congress on Infectious Diseases London, United kingdom |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The intended purpose of the meeting was to discuss and share information on effective strategies to prepare and respond to future pandemic threats. |
| Year(s) Of Engagement Activity | 2023 |
| Description | The National HIV and AIDS Scientific Meeting, 14th - 16th November 2023; Diminished Sensitivity of Historical and Contemporary HIV-1 Strains to Fusion Peptide Broadly Neutralizing Antibodies (bnAbs) may Call for A Reassessment of bnAbs Efficacy, Laban K, Susan M, Joseph Ssebwana Katende, Gerald Kevin Oluka, Yunia Mayanja, Sheila Balinda, Pontiano K, Jennifer S |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | We presented our study findings of " Diminished Sensitivity of Historical and Contemporary HIV-1 Strains to Fusion Peptide Broadly Neutralizing Antibodies (bnAbs) may Call for A Reassessment of bnAbs Efficacy" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://uac.go.ug/index.php?option=com_sppagebuilder&view=page&id=43&Itemid=351 |
| Description | Understanding the Uganda HIV Epidemic |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a presentation at the MRC/UVRI & LSHTM Inaugural Science Conference |
| Year(s) Of Engagement Activity | 2025 |
| Description | Using a registrational cohort to estimate background HIV incidence for an active-controlled pre-exposure prophylaxis trial: Lessons from PrEPVacc |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation was part of a panel on the topic estimating counterfactual HIV incidence, followed by many questions from the audience |
| Year(s) Of Engagement Activity | 2023 |
| Description | Validation of the Oxford Nanopore for identification of transmitted founder viruses |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Interractive and informative exhibition where the scientist show cased key information about the unit and its progress in HIV research |
| Year(s) Of Engagement Activity | 2023 |
| Description | Virologic characteristics of contemporary HIV-1 transmitted viruses in Uganda & Kenya |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Platform for Principal investigators to discuss respective research progress regarding HIV-1 vaccine development from Africa and India |
| Year(s) Of Engagement Activity | 2023 |
| Description | Virus Surveillance Pangea workshop |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Build capacity within the Virus Surveillance project team by training our CRCs, scientific investigators on machine learning and data analysis tools |
| Year(s) Of Engagement Activity | 2023 |
| Description | WHO National Measles Verification committee to discuss measles outbreaks and response outcomes |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discuss measles outbreaks and response outcomes |
| Year(s) Of Engagement Activity | 2023,2024 |